Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04285580 · ClinicalTrials.gov registry record · Phase 3
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 37
- Enrollment target
NCT04285580 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 37 participants.
The verdict
NCT04285580, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 37 participants
- Enrollment target
Study Summary
This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension
Interventions
- DRUG Bimatoprost SR
- DRUG LUMIGAN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2020-06-11 |
| Est. Completion | 2022-05-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04285580
The ClinicalTrials.gov registry entry for NCT04285580 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bimatoprost SR is the first listed.
NCT04285580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04285580 about?
NCT04285580 is a clinical study titled "A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension". This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension
What is the current status of trial NCT04285580?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 37 participants. The study started on 2020-06-11. Estimated completion is 2022-05-14.
What interventions are being tested in trial NCT04285580?
The interventions under investigation include: Bimatoprost SR (DRUG), LUMIGAN (DRUG).
Who is sponsoring clinical trial NCT04285580?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.